OTCMKTS:ALPMY - ASTELLAS PHARMA/ADR Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$16.15 +0.09 (+0.56 %)
(As of 07/20/2018 04:00 PM ET)
Previous Close$16.06
Today's Range$16.02 - $16.15
52-Week Range$11.86 - $16.19
Volume25,634 shs
Average Volume60,569 shs
Market Capitalization$31.87 billion
P/E Ratio20.90
Dividend Yield1.44%
Beta0.35
ASTELLAS PHARMA/ADR logoAstellas Pharma Inc., a pharmaceutical company, manufactures, markets, and imports and exports pharmaceutical products worldwide. The company offers Prograf and Advagraf/Graceptor/ASTAGRAF XL/Prograf XL, an immunosuppressant used to suppress organ transplant rejection; Vesicare, a treatment for overactive bladder; Harnal/Omnic, a blocking agent to treat the functional symptoms of benign prostatic hyperplasia; and Funguard/MYCAMIN, a candin-type antifungal agent. It also provides Geninax, an oral new-type quinolone antibacterial agent; Celecox, an anti-inflammatory agent; Lipitor, a treatment for hypercholesterolemia; Micardis/Micombi/Micamlo, a treatment for hypertension; Gaster, a treatment for peptic ulcer and gastritis; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic agonist indicated for the treatment of overactive bladder; Eligard, a luteinizing hormone-releasing hormone agonist for the treatment of prostate cancer; XTANDI for the treatment of prostate cancer; and VESOMNI, a release tablet for the treatment of moderate to severe storage symptoms and voiding symptoms associated with benign prostatic hyperplasia in men who are not adequately responding to treatment with monotherapy. In addition, the company offers Symbicort for the treatment for adult bronchial asthma and chronic obstructive pulmonary disease; Bonoteo for the treatment for osteoporosis; Suglat for the treatment of type 2 diabetes; and Repatha for the treatment of hypercholesterolemia. Further, the company provides Lexiscan, a pharmacologic stress agent; Tarceva, a treatment for non-small cell lung cancer; CRESEMBA, a azole antifungal; and Dificlir, a novel treatment for CDI. Additionally, it is developing enzalutamide, gilteritinib, and degarelix for oncology indications. The company has a collaborative and license agreement with Proteostasis Therapeutics, Inc. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.

Receive ALPMY News and Ratings via Email

Sign-up to receive the latest news and ratings for ALPMY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:ALPMY
CUSIPN/A
Phone813-3244-3000

Debt

Debt-to-Equity RatioN/A
Current Ratio2.34
Quick Ratio1.97

Price-To-Earnings

Trailing P/E Ratio20.90
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$12.00 billion
Price / Sales2.66
Cash Flow$1.2079 per share
Price / Cash13.37
Book Value$5.27 per share
Price / Book3.06

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$1.52 billion
Net Margins13.34%
Return on Equity12.96%
Return on Assets9.13%

Miscellaneous

EmployeesN/A
Outstanding Shares1,980,000,000
Market Cap$31,868.10

ASTELLAS PHARMA/ADR (OTCMKTS:ALPMY) Frequently Asked Questions

What is ASTELLAS PHARMA/ADR's stock symbol?

ASTELLAS PHARMA/ADR trades on the OTCMKTS under the ticker symbol "ALPMY."

When did ASTELLAS PHARMA/ADR's stock split? How did ASTELLAS PHARMA/ADR's stock split work?

Shares of ASTELLAS PHARMA/ADR split before market open on Wednesday, April 2nd 2014. The 5-4 split was announced on Friday, March 14th 2014. The newly minted shares were distributed to shareholders after the market closes on Tuesday, April 1st 2014. An investor that had 100 shares of ASTELLAS PHARMA/ADR stock prior to the split would have 125 shares after the split.

How were ASTELLAS PHARMA/ADR's earnings last quarter?

ASTELLAS PHARMA/ADR (OTCMKTS:ALPMY) released its quarterly earnings results on Wednesday, April, 25th. The company reported $0.10 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.15 by $0.05. The company earned $2.78 billion during the quarter. ASTELLAS PHARMA/ADR had a return on equity of 12.96% and a net margin of 13.34%. View ASTELLAS PHARMA/ADR's Earnings History.

When is ASTELLAS PHARMA/ADR's next earnings date?

ASTELLAS PHARMA/ADR is scheduled to release their next quarterly earnings announcement on Thursday, July, 26th 2018. View Earnings Estimates for ASTELLAS PHARMA/ADR.

What is the consensus analysts' recommendation for ASTELLAS PHARMA/ADR?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ASTELLAS PHARMA/ADR in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold."

Who are some of ASTELLAS PHARMA/ADR's key competitors?

Who are ASTELLAS PHARMA/ADR's key executives?

ASTELLAS PHARMA/ADR's management team includes the folowing people:
  • Mr. Kenji Yasukawa Ph.D., Pres, CEO & Director (Age 58)
  • Mr. Stephen Knowles, Sr. VP of Fin. & Information Technology
  • Mr. Percival Barretto-Ko, Sr. VP of International Operations
  • Mr. Chikashi Takeda, Corp. Exec. and Corp. VP of Corp. Fin. & Control
  • Mr. Fumiaki Sakurai, Chief Admin. Officer & Chief Ethics & Compliance Officer

Has ASTELLAS PHARMA/ADR been receiving favorable news coverage?

Headlines about ALPMY stock have trended somewhat positive this week, according to Accern. The research group ranks the sentiment of news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. ASTELLAS PHARMA/ADR earned a daily sentiment score of 0.16 on Accern's scale. They also gave media stories about the company an impact score of 46.25 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

How do I buy shares of ASTELLAS PHARMA/ADR?

Shares of ALPMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ASTELLAS PHARMA/ADR's stock price today?

One share of ALPMY stock can currently be purchased for approximately $16.15.

How big of a company is ASTELLAS PHARMA/ADR?

ASTELLAS PHARMA/ADR has a market capitalization of $31.87 billion and generates $12.00 billion in revenue each year.

How can I contact ASTELLAS PHARMA/ADR?

ASTELLAS PHARMA/ADR's mailing address is 2-5-1 Nihonbashi-Honcho Chuo-Ku, Tokyo M0, 103-8411. The company can be reached via phone at 813-3244-3000.


MarketBeat Community Rating for ASTELLAS PHARMA/ADR (OTCMKTS ALPMY)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  118 (Vote Outperform)
Underperform Votes:  71 (Vote Underperform)
Total Votes:  189
MarketBeat's community ratings are surveys of what our community members think about ASTELLAS PHARMA/ADR and other stocks. Vote "Outperform" if you believe ALPMY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALPMY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.